The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1543
Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes
The full article is available to subscribers Subscriber Login   

The FDA has approved Qtern (AstraZeneca), a fixed-dose combination of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) and the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin (Onglyza), for oral treatment of adults with type 2 diabetes. Dapagliflozin and saxagliptin have each been available for years alone and in combination with extended-release metformin (Xigduo XR; Kombiglyze XR).1 Three SGLT2/DPP-4 inhibitor combinations are now available in the US (see Table 2).

CLINICAL STUDIES — In a trial in 320 patients with a glycated hemoglobin (A1C) of 7-10.5% who were stabilized on open-label treatment with metformin and saxagliptin 5 mg/day for 8-16 weeks and then randomized to addition of dapagliflozin 10 mg/day or placebo for 24 weeks, the mean change from baseline in A1C, the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes
Article code: 1543d
 Electronic, downloadable article - $25